Dr. Fisher on Bortezomib/R-CHOP Combo for Mantle Cell Lymphoma

Richard Fisher
Published: Wednesday, Jan 07, 2015



Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.

A phase 2 study of this combination showed promising results. While the level of toxicities were minimal during the trial, there were some cases of neurotoxicity.
Fisher says that the results of the trial show the potential of bortezomib as a treatment option for patients with mantle cell lymphoma.


Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.

A phase 2 study of this combination showed promising results. While the level of toxicities were minimal during the trial, there were some cases of neurotoxicity.
Fisher says that the results of the trial show the potential of bortezomib as a treatment option for patients with mantle cell lymphoma.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x